Endometrial stromal sarcoma of twenty cases.
BACKGROUND
Endometrial stromal sarcoma is a rare neoplasm. We reviewed twenty cases to study the characteristics of this disease.


METHODS
Twenty cases of endometrial stromal sarcoma were treated at our hospital. The clinical stage, treatment and outcome were retrospectively analyzed.


RESULTS
Endometrial stromal sarcoma comprised 4.3% of corpus cancers and 46.4% of uterine sarcomas at our hospital. Seven cases were stage I, one was stage II, ten were stage III, and two were stage IV at the time of diagnosis. Histopathologically, seventeen cases were classified as low-grade sarcoma and three were high-grade sarcoma. Seven patients had recurrence and five of them had already died of disease. Among these recurrent patients, one was stage II and six were stage III. All three patients with high-grade sarcoma and four with low-grade sarcoma had recurrence.


CONCLUSIONS
We think mitotic count is an important prognostic factor in low-grade endometrial stromal sarcoma and high-grade endometrial stromal sarcoma has a poor prognosis even with post-operative adjuvant treatment.
Huang
K T
KT
Department of Obstetrics and Gynecology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen
C A
CA
Tseng
G C
GC
Chen
T M
TM
Cheng
W F
WF
Hsieh
C Y
CY
D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D004717:Endometrium / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008854:Microscopy, Electron; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018203:Sarcoma, Endometrial Stromal / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D014463:Ultrasonography
D000277:Adjuvants, Pharmaceutic; D000970:Antineoplastic Agents